Daratumumab Improves Depth of Response and Progression-Free Survival in Transplant-Ineligible, High-Risk Newly Diagnosed Multiple Myeloma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Oncologist
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Daratumumab Improves Depth of Response and Progression-free Survival in Transplant-ineligible, High-risk, Newly Diagnosed Multiple Myeloma
Oncologist 2022 Apr 24;[EPub Ahead of Print], AJ Jakubowiak, S Kumar, R Medhekar, H Pei, P Lefebvre, S Kaila, J He, MH Lafeuille, A Cortoos, A Londhe, P Mavros, TS Lin, SZ UsmaniFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.